Extracorporeal photopheresis in psoriasis vulgaris: Clinical and immunologic observations

E. C. Vonderheid, C. A. Kang, M. Kadin, R. D. Bigler, T. D. Griffin, T. J. Rogers

Research output: Contribution to journalArticle

Abstract

Four patients with chronic refractory plaque-type psoriasis without arthropathy were treated with extracorporeal photopheresis every other week for 6 to 13 months. In patients 1 and 2, methotrexate was administered concomitantly during the initial part of the trial; the dose was gradually tapered and the drug was discontinued by 6 months. Both patients improved to 23% and 62% of baseline values for percentage of body surface involvement, but their disease then flared when maintenance extracorporeal photopheresis was used alone. Substantial improvement again occurred when lower doses of methotrexate were administered with extracorporeal photopheresis. Patients 3 and 4 were treated initially with extracorporeal photopheresis alone and both improved to 50% and 52% of baseline body surface involvement, respectively, after 4 months of treatment. However, their disease flared because of factors unrelated to treatment. Extracorporeal photopheresis was well tolerated by all patients without evidence of overt toxicity. However, prolonged treatment with extracorporeal photopheresis/methotrexate was accompanied by a decrease in skin reactivity to recall antigens and by decreased capacity of lymphocytes to produce interleukin 2 in response to polyclonal stimuli in vitro. These findings indicate that alternate-week extracorporeal photopheresis has a definite but incomplete suppressive effect on psoriasis vulgaris that may be mediated through an effect on lymphokine production by photomodified cells and that the therapeutic effect of extracorporeal photopheresis may be enhanced by concomitant administration of low doses of methotrexate.

Original languageEnglish (US)
Pages (from-to)703-712
Number of pages10
JournalJournal of the American Academy of Dermatology
Volume23
Issue number4 I
StatePublished - 1990
Externally publishedYes

Fingerprint

Photopheresis
Psoriasis
Methotrexate
Joint Diseases
Lymphokines
Therapeutic Uses
Interleukin-2
Therapeutics
Maintenance
Lymphocytes
Antigens
Skin

ASJC Scopus subject areas

  • Dermatology

Cite this

Vonderheid, E. C., Kang, C. A., Kadin, M., Bigler, R. D., Griffin, T. D., & Rogers, T. J. (1990). Extracorporeal photopheresis in psoriasis vulgaris: Clinical and immunologic observations. Journal of the American Academy of Dermatology, 23(4 I), 703-712.

Extracorporeal photopheresis in psoriasis vulgaris : Clinical and immunologic observations. / Vonderheid, E. C.; Kang, C. A.; Kadin, M.; Bigler, R. D.; Griffin, T. D.; Rogers, T. J.

In: Journal of the American Academy of Dermatology, Vol. 23, No. 4 I, 1990, p. 703-712.

Research output: Contribution to journalArticle

Vonderheid, EC, Kang, CA, Kadin, M, Bigler, RD, Griffin, TD & Rogers, TJ 1990, 'Extracorporeal photopheresis in psoriasis vulgaris: Clinical and immunologic observations', Journal of the American Academy of Dermatology, vol. 23, no. 4 I, pp. 703-712.
Vonderheid EC, Kang CA, Kadin M, Bigler RD, Griffin TD, Rogers TJ. Extracorporeal photopheresis in psoriasis vulgaris: Clinical and immunologic observations. Journal of the American Academy of Dermatology. 1990;23(4 I):703-712.
Vonderheid, E. C. ; Kang, C. A. ; Kadin, M. ; Bigler, R. D. ; Griffin, T. D. ; Rogers, T. J. / Extracorporeal photopheresis in psoriasis vulgaris : Clinical and immunologic observations. In: Journal of the American Academy of Dermatology. 1990 ; Vol. 23, No. 4 I. pp. 703-712.
@article{2850251c6793423a8bd7c93d61eacd6a,
title = "Extracorporeal photopheresis in psoriasis vulgaris: Clinical and immunologic observations",
abstract = "Four patients with chronic refractory plaque-type psoriasis without arthropathy were treated with extracorporeal photopheresis every other week for 6 to 13 months. In patients 1 and 2, methotrexate was administered concomitantly during the initial part of the trial; the dose was gradually tapered and the drug was discontinued by 6 months. Both patients improved to 23{\%} and 62{\%} of baseline values for percentage of body surface involvement, but their disease then flared when maintenance extracorporeal photopheresis was used alone. Substantial improvement again occurred when lower doses of methotrexate were administered with extracorporeal photopheresis. Patients 3 and 4 were treated initially with extracorporeal photopheresis alone and both improved to 50{\%} and 52{\%} of baseline body surface involvement, respectively, after 4 months of treatment. However, their disease flared because of factors unrelated to treatment. Extracorporeal photopheresis was well tolerated by all patients without evidence of overt toxicity. However, prolonged treatment with extracorporeal photopheresis/methotrexate was accompanied by a decrease in skin reactivity to recall antigens and by decreased capacity of lymphocytes to produce interleukin 2 in response to polyclonal stimuli in vitro. These findings indicate that alternate-week extracorporeal photopheresis has a definite but incomplete suppressive effect on psoriasis vulgaris that may be mediated through an effect on lymphokine production by photomodified cells and that the therapeutic effect of extracorporeal photopheresis may be enhanced by concomitant administration of low doses of methotrexate.",
author = "Vonderheid, {E. C.} and Kang, {C. A.} and M. Kadin and Bigler, {R. D.} and Griffin, {T. D.} and Rogers, {T. J.}",
year = "1990",
language = "English (US)",
volume = "23",
pages = "703--712",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4 I",

}

TY - JOUR

T1 - Extracorporeal photopheresis in psoriasis vulgaris

T2 - Clinical and immunologic observations

AU - Vonderheid, E. C.

AU - Kang, C. A.

AU - Kadin, M.

AU - Bigler, R. D.

AU - Griffin, T. D.

AU - Rogers, T. J.

PY - 1990

Y1 - 1990

N2 - Four patients with chronic refractory plaque-type psoriasis without arthropathy were treated with extracorporeal photopheresis every other week for 6 to 13 months. In patients 1 and 2, methotrexate was administered concomitantly during the initial part of the trial; the dose was gradually tapered and the drug was discontinued by 6 months. Both patients improved to 23% and 62% of baseline values for percentage of body surface involvement, but their disease then flared when maintenance extracorporeal photopheresis was used alone. Substantial improvement again occurred when lower doses of methotrexate were administered with extracorporeal photopheresis. Patients 3 and 4 were treated initially with extracorporeal photopheresis alone and both improved to 50% and 52% of baseline body surface involvement, respectively, after 4 months of treatment. However, their disease flared because of factors unrelated to treatment. Extracorporeal photopheresis was well tolerated by all patients without evidence of overt toxicity. However, prolonged treatment with extracorporeal photopheresis/methotrexate was accompanied by a decrease in skin reactivity to recall antigens and by decreased capacity of lymphocytes to produce interleukin 2 in response to polyclonal stimuli in vitro. These findings indicate that alternate-week extracorporeal photopheresis has a definite but incomplete suppressive effect on psoriasis vulgaris that may be mediated through an effect on lymphokine production by photomodified cells and that the therapeutic effect of extracorporeal photopheresis may be enhanced by concomitant administration of low doses of methotrexate.

AB - Four patients with chronic refractory plaque-type psoriasis without arthropathy were treated with extracorporeal photopheresis every other week for 6 to 13 months. In patients 1 and 2, methotrexate was administered concomitantly during the initial part of the trial; the dose was gradually tapered and the drug was discontinued by 6 months. Both patients improved to 23% and 62% of baseline values for percentage of body surface involvement, but their disease then flared when maintenance extracorporeal photopheresis was used alone. Substantial improvement again occurred when lower doses of methotrexate were administered with extracorporeal photopheresis. Patients 3 and 4 were treated initially with extracorporeal photopheresis alone and both improved to 50% and 52% of baseline body surface involvement, respectively, after 4 months of treatment. However, their disease flared because of factors unrelated to treatment. Extracorporeal photopheresis was well tolerated by all patients without evidence of overt toxicity. However, prolonged treatment with extracorporeal photopheresis/methotrexate was accompanied by a decrease in skin reactivity to recall antigens and by decreased capacity of lymphocytes to produce interleukin 2 in response to polyclonal stimuli in vitro. These findings indicate that alternate-week extracorporeal photopheresis has a definite but incomplete suppressive effect on psoriasis vulgaris that may be mediated through an effect on lymphokine production by photomodified cells and that the therapeutic effect of extracorporeal photopheresis may be enhanced by concomitant administration of low doses of methotrexate.

UR - http://www.scopus.com/inward/record.url?scp=0025038678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025038678&partnerID=8YFLogxK

M3 - Article

C2 - 2229499

AN - SCOPUS:0025038678

VL - 23

SP - 703

EP - 712

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4 I

ER -